- Home
- ALZN
ALZN
Alzamend Neuro Inc.
as 04-24-2025 4:00pm EST
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 6.1M | IPO Year: | 2021 |
| Target Price: | $20.00 | AVG Volume (30 days): | 124.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.64 - $15.06 | Next Earning Date: | 03-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 322.64% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Alzamend Neuro Inc. (ALZN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horne William B. | ALZN | Director | Mar 26 '25 | Buy | $0.99 | 3,334 | $3,285.32 | 30,000 | |
| AULT MILTON C III | ALZN | Director10% Owner | Mar 21 '25 | Buy | $1.02 | 2,905 | $2,968.91 | 85,273 | |
| Katzoff David J | ALZN | Chief Financial Officer | Mar 21 '25 | Buy | $1.01 | 5,000 | $5,048.00 | 5,540 | |
| Horne William B. | ALZN | Director | Mar 20 '25 | Buy | $0.98 | 5,000 | $4,891.50 | 30,000 | |
| AULT MILTON C III | ALZN | Director10% Owner | Mar 18 '25 | Buy | $0.96 | 5,000 | $4,810.00 | 85,273 | |
| Horne William B. | ALZN | Director | Mar 18 '25 | Buy | $0.97 | 5,000 | $4,851.50 | 30,000 | |
| AULT MILTON C III | ALZN | Director10% Owner | Mar 12 '25 | Buy | $0.68 | 100 | $68.42 | 85,273 |
Latest Alzamend Neuro Inc. News
ALZN Breaking Stock News: Dive into ALZN Ticker-Specific Updates for Smart Investing
Zacks
16 days ago
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Insider Monkey
a month ago
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?
GlobeNewswire
a month ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
GlobeNewswire
a month ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
GlobeNewswire
a month ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
GlobeNewswire
2 months ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
GlobeNewswire
2 months ago
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Benzinga
2 months ago
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Compare ALZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALZN Alzamend Neuro Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.